推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D +75 to +90°, c = 1 in dichloromethane
顏色
white to tan
溶解度
DMSO: ≥19 mg/mL
儲存溫度
2-8°C
SMILES 字串
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]23C
InChI
1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
InChI 密鑰
WJOHZNCJWYWUJD-IUGZLZTKSA-N
基因資訊
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
生化／生理作用
Flucinonide is a fluorinated glucocorticid that is used as a topical anti-inflammatory agent. Recently, flucinonide and other fluorinated glucocorticolids were identified as smoothend agonists. Flucinonide induces expression of Gli-reporter luciferase in Shh-LIGHT2 cells.
Fluocinonide has been used to study its effect on T-cell proliferation.
Fluocinonide is shown to be effective in the treatment of atopic dermatitis and oral lichen planus (OLP).
very potent corticosteroid
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 2 Oral - Repr. 2
儲存類別代碼
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
N Deslauriers et al.
FEMS immunology and medical microbiology, 11(1), 45-55 (1995-03-01)
Using an experimental model in the mouse we have shown that both local and central lines of defense, involving CD4+ T cells, participate in a dynamic interaction to maintain a long-term carrier state of Candida albicans in the oral cavity.
Emily Hix et al.
Dermatology online journal, 19(10), 20029-20029 (2013-10-22)
Adherence in the treatment of chronic inflammatory skin diseases such as atopic dermatitis is poor. Methods to improve adherence have proven difficult. To determine whether a short course of treatment with a high-potency corticosteroid will improve adherence compared to longer
Mondhipa Ratnarathorn et al.
Dermatology online journal, 14(8), 6-6 (2008-12-09)
Sneddon-Wilkinson disease or subcorneal pustular dermatosis (SPD) is a rare, benign inflammatory skin disorder of unknown etiology. SPD is associated with various systemic disorders, including immunoglobinopathies and lymphoproliferative disorders. The relationship between SPD and immune dysfunction is unlikely to be
Salma Pothiawala et al.
Journal of drugs in dermatology : JDD, 9(9), 1142-1144 (2010-09-28)
Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers. Temozolomide is well tolerated, and the reported dermatologic
Tinea incognito.
Rhonda Lesniak
Dermatology nursing, 20(5), 403-404 (2008-12-06)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门